CLINICAL TRIALS AND OBSERVATIONS Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML
نویسندگان
چکیده
Jessica A. Pollard,1,2 Todd A. Alonzo,3,4 Robert B. Gerbing,4 Phoenix A. Ho,1,2 Rong Zeng,1 Yaddanapudi Ravindranath,5 Gary Dahl,6 Norman J. Lacayo,6 David Becton,7 Myron Chang,8 Howard J. Weinstein,9 Betsy Hirsch,10 Susana C. Raimondi,11 Nyla A. Heerema,12 William G. Woods,13 Beverly J. Lange,14 Craig Hurwitz,15 Robert J. Arceci,16 Jerald P. Radich,1 Irwin D. Bernstein,1,2 Michael C. Heinrich,17 and Soheil Meshinchi1,2
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Clinical implications of FLT3 mutations in pediatric AML
Activating mutations of the FLT3 gene occur because of an internal tandem duplication of the juxta-membrane domain (FLT3/ITD) or point mutation of the activation loop domain (FLT3/ALM). The presence of FLT3 mutations as well as the allelic ratio of FLT3/ITD (ITD-AR, mutant– wild type ratio) may have prognostic significance. FLT3 mutation status of 630 children with de novo acute myeloid leukemi...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study
Distinct forms of tyrosine kinase domain (TKD), juxtamembrane domain, exon 8, and internal tandem duplication (ITD) mutations of c-KIT, were observed in about 46% of core binding factor leukemia (CBFL) patients. To evaluate their prognostic significance, 67 adult patients with CBFL were analyzed to ascertain the cKIT mutation status. In acute myeloid leukemia (AML) with t(8;21), the presence of...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
The clinical value of serial minimal residual disease (MRD) monitoring in core binding factor (CBF) acute myeloid leukemia (AML) by quantitative RT-PCR was prospectively assessed in 278 patients [163 with t(8;21) and 115 with inv(16)] entered in the United Kingdom MRC AML 15 trial. CBF transcripts were normalized to 105 ABL copies. At remission, after course 1 induction chemotherapy, a > 3 log ...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately 30% of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure rates from standard chemotherapy-based treatment. Targeting the mutation by inhibiting the tyrosine kinase activity of FLT3 is cytotoxic to cell lines and primary AML cells harboring FLT3 mutations. Successful FLT3 in...
متن کاملPrognostic Importance of Mutations in the rus Proto-Oncogenes in De Novo Acute Myeloid Leukemia
Mutations of the Nand K-ras genes are the most frequent genetic aberrations in acute myeloid leukemia (AML) and their detection in preleukemic conditions such as the myelodysplastic syndrome (MDS) suggests a role in the earliest phases of leukemogenesis. Despite these observations, little is known about the clinical importance of ras mutations in AML. We studied the clinical impact of ras mutat...
متن کامل